| 引用本文: | 武彩霞,崔景荣.内皮素及其受体拮抗剂与肿瘤[J].中国现代应用药学,2011,28(5):416-422. |
| WU Caixia,CUI Jingrong.Endotheline, Endotheline Receptor Antagonist and Neoplasm[J].Chin J Mod Appl Pharm(中国现代应用药学),2011,28(5):416-422. |
|
| 摘要: |
| 目的 分析内皮素系统与肿瘤发生发展的关系，为内皮素受体成为抗肿瘤药物新的作用靶点提供依据，同时为抗肿瘤药物研究提供新思路。方法 检索2000—2010年国内外医学期刊中内皮素系统与肿瘤发生发展及内皮素受体拮抗剂与肿瘤治疗的资料，综述内皮素及其受体拮抗剂与肿瘤的关系。结果 内皮素受体是抗肿瘤药物新的作用靶点。结论 内皮素受体拮抗剂将成为肿瘤治疗中的新型药物。 |
| 关键词: 内皮素 内皮素受体拮抗剂 肿瘤 |
| DOI： |
| 分类号: |
| 基金项目:2008年山东省高等学校优秀青年教师国内访问学者资助项目 |
|
| Endotheline, Endotheline Receptor Antagonist and Neoplasm |
|
WU Caixia,CUI Jingrong
|
| Abstract: |
| OBJECTIVE The review discussed the relationship between endothelin system and the development of tumors, showing that endothelin receptor may be a novel target of anticancer drugs, and providing new ideas on anticancer drug research. METHODS The domestic and foreign data, regarding endothelin system in tumor development and endothelin receptor antagonist in tumor treatment from 2000 to 2010, were retrieved, and the relationship between endothelin system and the development/treatment of tumor was reviewed. RESULTS Endothelin receptor is a novel target of anticancer drugs．CONCLUSION Endothelin receptor antagonist will be a promising agent in the treatment of cancer. |
| Key words: endothelin endothelin receptor antagonists neoplasm |
